iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Biocon Ltd News Today

333.7
(0.21%)
Mar 7, 2025|03:31:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Company

Sectoral

Biocon Biologics inks pact with Civica to expand access in US

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

7 Mar 2025|08:53 AM
Biocon Secures USFDA Approval for Dasatinib

The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.

5 Mar 2025|01:40 PM
Biocon launches generic Liraglutide in the UK

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.

28 Feb 2025|01:53 PM
Biocon Biologics introduces stelara biosimilar YESINTEK in US

As per the company, YESINTEK shall be available in all the same formulations currently provided by Stelara.

25 Feb 2025|09:00 AM
Top Stocks for Today - 25th February 2025

Here are some of the stocks that may see significant price movement today: Biocon, NTPC Green Energy, LIC, etc.

25 Feb 2025|07:03 AM
Biocon Q3 Revenue Up 10%, EBITDA Rises 16%

Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.

31 Jan 2025|11:07 AM
Top Stocks for Today - 13th January 2025

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Just Dial, PCBL, etc.

13 Jan 2025|07:29 AM
Biocon unit gets approval for Tacrolimus capsules in China

The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously

3 Jan 2025|09:44 AM
Top Stocks for 3rd January 2025

Here are some of the stocks that may see significant price movement today: Varun Beverages, NHPC, Hindustan Zinc, etc.

3 Jan 2025|07:01 AM
Biocon Gets USFDA Clearance and EU Nod for Diabetes Drug

The USFDA released an Establishment Inspection Report with a "Voluntary Action Indicated" status for Biocon's Active Pharmaceutical Ingredients facility in Bengaluru.

27 Dec 2024|03:28 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.